+44 20 8123 2220
info@marketpublishers.com

Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023

https://marketpublishers.com/r/G18D77FF348EN.html
Date: October 2017
Pages: 190
Price: US$ 2,400.00 (Single User License)
ID: G18D77FF348EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023” report gives comprehensive insight on clinical and non-clinical parameters related to development and commercialization of cancer janus kinase inhibitor market. As per report findings, janus kinase inhibitors have emerged as one of the new potential candidate and growth frontier for the various stake holders involved in the research and development of cancer drugs and therapies. At present there is only one janus kinase inhibitors based drug commercially available in the market and 27 drugs are in the various clinical development phases. Most of the drugs are in Preclinical phase (13 Drugs) followed by the Phase-II (4 Drugs) clinical trials.

“Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023” Highlights:

Mechanism of Action of JAK/STAT Inhibitors

Global Cancer JAK/STAT Inhibitor Market Outlook

Global JAK/STAT Inhibitor Market Opportunity: US$ 4 Billion

Global JAK/STAT Inhibitor in Pipeline: 27 Drugs

Global Cancer JAK/STAT Inhibitor Therapy Price Analysis

Global Cancer JAK/STAT Inhibitor Market Dynamics

+44 20 8123 2220
info@marketpublishers.com

Global Cancer Janus Kinase Inhibitors Clinical Pipeline by Company & Phase

Marketed Cancer Janus Kinase Inhibitors Clinical Insight

Comparative Price Analysis of JAK/STAT Inhibitors & Conventional Cancer Therapies

The conventional modes of cancer management including surgery, radiotherapy and chemotherapy were discarded as an aspirant for the future of cancer management long back ago. The arrival of modern cancer treatment modalities like immunotherapy and targeted therapy revolutionized the outlook of the future of cancer management. Amongst both of the modern therapies, targeted therapies have shown an impressive growth in a very short duration of time. The targeted therapies developed rapidly and gained much importance in the global market for cancer therapeutics due to their advantages over the conventional therapies. Targeted therapies are safer and more efficient approach for managing cancer. The only drawback for targeted therapies was that only a few targets were available for developing cancer therapeutics. The high efficacy of targeted therapeutics for cancer raised the demand for identifying new targets.

JAK/STAT inhibitor being the latest invention in the field of targeted therapies is considered as the best available therapy for cancer by many scientific researchers. JAK/STAT inhibitors target the process involved in the production of the damaged DNA which is playing the major role in developing cancerous cells. The available JAK/STAT inhibitors are highly focused on treating the rare hematological malignancies like myelofibrosis, polycythemia Vera and primary thrombocythemia. However, the continuous efforts of the research community has led to the identification of the role of JAK/STAT pathway in a wide range of tumors including solid tumors like lung cancer, pancreatic cancer, prostate cancer, breast cancer, colorectal cancer, ovarian cancer, gastrointestinal cancers etc.

The global revenue collection from currently available JAK/STAT inhibitor drug; Ruxolitinib, has been very impressive since its approval. Although the drug is approved for treating rare hematological malignancies but incidence rate of these cancers has been found to be increasing in the past five years. Furthermore, the lack of effective treatment for such cancers and increased survival rates of the patients after getting a treatment with Ruxolitinib has aided the commercial success of Ruxolitinib.

+44 20 8123 2220
info@marketpublishers.com

More than 5 JAK/STAT inhibitors are expected to enter the cancer therapeutic market in the next decade. The development of JAK/STAT inhibitors has been so impressive and rapid in the past five years that a great economic success of this class of drugs is expected in the nearby future. Additionally, huge commercial success of the JAK inhibitor Ruxolitinib for myeloproliferative disorders has further accelerated the development of more JAK/STAT inhibitors. Advancements in research and technology will aid the development of JAK/STAT inhibitors. The development of more JAK/STAT inhibitors will not only provide benefits to the cancer therapeutic market but will also provide a better life to the patients suffering from cancers.

Past success of JAK/STAT inhibitors has provided an overview of its future market. The clinical success of JAK inhibitor, Ruxolitinib has gained adequate popularity among the patients and the physicians. Due to this reason, the demand of JAK/STAT inhibitors is highly increased. Furthermore, the popularity of Ruxolitinib will aid the market success of other JAK/STAT inhibitory drugs which are going to be licensed very soon.

+44 20 8123 2220
info@marketpublishers.com

Contents

1. PROLOGUE TO JAK/STAT PATHWAY

1.1 Overview
1.2 Categorization of JAK/STAT Inhibitors in Cancer Therapeutics

2. ROLE OF JAK/STAT PATHWAY IN TUMOR FORMATION

3. JAK/STAT INHIBITORS: MODERN THERAPEUTICS FOR EFFECTIVE CANCER MANAGEMENT

4. UNDERSTANDING THE TARGETS FOR INHIBITION: AN INSIGHT INTO JAK & STAT PROTEINS

4.1 Structure & Significance
  4.1.1 Janus Kinases: A Novel Cytokine Receptor
  4.1.2 STAT Proteins: The Signal Generators for Transcription
4.2 Importance of Modulation of JAK/STAT in a Healthy Cell

5. MECHANISM OF ACTION OF JAK/STAT INHIBITORS

6. IDENTIFICATION OF ACTIVE TARGET IN TUMOR CELLS FOR JAK/STAT INHIBITION

6.1 Cell Based Assays
6.2 Biochemical Assays

7. NEED & SUPERIORITY OF JAK/STAT INHIBITORS: ITS IMPORTANCE IN MODERN CANCER THERAPY

8. JAK/STAT INHIBITORS IN CANCER THERAPY

8.1 Hematological Malignancies
  8.1.1 Myelofibrosis
  8.1.2 Acute Lymphoblastic Leukemia
  8.1.3 Polycythemia Vera
  8.1.4 Primary thrombocythemia
8.2 Solid Tumors

+44 20 8123 2220
info@marketpublishers.com

8.2.1 Lung Cancer
8.2.2 Ovarian Cancer
8.2.3 Breast Cancer
8.2.4 Pancreatic Cancer
8.2.5 Hepatocellular Carcinoma
8.2.6 Colorectal cancer
8.2.7 Head & Neck Squamous Cell Carcinoma
8.2.8 Prostate Cancer
8.2.9 Glioblastoma
8.2.10 Other Solid Tumors

9. CANCER JAK/STAT INHIBITOR DRUGS

9.1 Approved Drugs
9.1.1 Ruxolitinib
9.2 Promising Candidates in the Clinical Pipeline
9.2.1 Momelotinib
9.2.2 Lestaurtinib
9.2.3 Pacritinib

10. GLOBAL CANCER JAK/STAT INHIBITOR MARKET OUTLOOK

10.1 Current Scenario
10.2 Clinical Pipeline Overview

11. GLOBAL CANCER JAK/STAT INHIBITOR THERAPY PRICE ANALYSIS

11.1 Analyzing the Cost of Available JAK/STAT Inhibitor
11.2 Comparative Price Analysis of JAK/STAT Inhibitors and Best Available Therapy
11.3 Comparative Price Analysis of JAK/STAT Inhibitors & Conventional Cancer Therapies
11.4 Comparative Price Analysis of JAK/STAT Inhibitors & Newly Approved Anti-Cancer Therapeutics

12. GLOBAL CANCER JAK/STAT INHIBITOR MARKET DYNAMICS

12.1 Favorable Factors for Cancer JAK/STAT Inhibitors Market
12.1.1 Elevation in Disease Burden
12.1.2 Unmet Medical Need

+44 20 8123 2220
info@marketpublishers.com

12.1.3 Advancement in Technology
12.1.4 Strong Clinical Pipeline
12.1.5 Orphan Drug Status to JAK/STAT Inhibitors
12.1.6 Commercial Success of Ruxolitinib
12.2 Market challenges for Cancer JAK/STAT Inhibitors
12.2.1 Scientific Limitations and the Number of Side Effects
12.2.2 Clinical Hold on Pacritinib
12.2.3 Tedious approval process

13. GLOBAL CANCER JAK/STAT INHIBITOR MARKET FUTURE OUTLOOK

14. GLOBAL CANCER JANUS KINASE INHIBITORS CLINICAL PIPELINE BY COMPANY & PHASE

14.1 Research
14.2 Preclinical
14.3 Phase-I
14.4 Phase-I/II
14.5 Phase-II
14.6 Phase-III
14.7 Preregistration

15. MARKETED CANCER JANUS KINASE INHIBITORS CLINICAL INSIGHT BY COMPANY

15.1 Ruxolitinib (Jakafi & Jakavi)

16. SUSPENDED CANCER JANUS KINASE INHIBITORS IN CLINICAL PIPELINE BY COMPANY & PHASE

16.1 No Development Reported
16.2 Discontinued

17. COMPETITIVE LANDSCAPE

17.1 Abbott Laboratories
17.2 Asana Biosciences
17.3 Astra Zeneca
17.4 Celon Pharmaceuticals

+44 20 8123 2220
info@marketpublishers.com

17.5 Dynamic Pharma
17.6 Eli Lilly
17.7 Gilead Sciences
17.8 Hanmi Pharmaceuticals
17.9 Incyte
17.10 Kyowa Hakko
17.11 Moleculin
17.12 Pfizer
17.13 PIQUR Therapeutics
17.14 Portola Pharmaceuticals
17.15 S*BIO

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1-1: Conventional Approaches for Treating Cancer
Figure 1-2: Major Limitations of Conventional Cancer Therapies
Figure 1-3: Modern Approach in Cancer Therapy
Figure 1-4: Major Types of Cancer Treatment Modalities
Figure 1-5: Categorization of JAK Inhibitors in Targeted Therapies
Figure 3-1: Advanced Approaches for the Development of JAK/STAT Inhibitors
Figure 4-1: Architecture of the Structure of Janus Kinase
Figure 4-2: Cis Mode of Activation of Janus Kinase
Figure 4-3: Trans Mode of Activation of Janus Kinase
Figure 4-4: Architecture of the Structure of STAT Proteins
Figure 4-5: Activation of STAT Proteins
Figure 4-6: Natural Inhibitors of JAK/STAT Signaling Pathway
Figure 5-1: JAK/STAT Signaling Pathway in Normal Human Cell
Figure 5-2: JAK/STAT Pathway in Hematological Cancers
Figure 5-3: Mechanism of Action of JAK inhibitors
Figure 6-1: Technologies Used For Diagnosing JAK/STAT Pathway in Tumor Cells
Figure 7-1: Advanced Features of JAK/STAT Inhibitors in Cancer Therapy
Figure 8-1: JAK/STAT Mutations in Hematological Malignancies
Figure 9-1: Target & Effects of Ruxolitinib
Figure 9-2: Impact of Ruxolitinib on Change in Mean Spleen Size
Figure 10-1: Global Prevalence - Myelofibrosis Patients (Numbers), 2015-17
Figure 10-2: Global Prevalence - Polycythemia Vera Patients (Numbers), 2015-17
Figure 10-3 Global Prevalence - Primary Thrombocythemia Patients (Numbers), 2015-17
Figure 10-4 : Global- Ruxolitinib Revenue for Myelofibrosis (US$ Million), 2015-2017
Figure 10-5: Global - Ruxolitinib Revenue for Polycythemia Vera (US$ Million), 2015-2017
Figure 10-6: Global- Ruxolitinib Revenue for Primary Thrombocythemia (US$ Million), 2015-2017
Figure 10-7: Global- Ruxolitinib Revenue by Hematological Malignancies (%), 2016
Figure 10-8: Global Janus Kinase Inhibitors Cancer Clinical Pipeline by Phase (%), 2017 till 2023
Figure 10-9: Global Janus Kinase Inhibitors Cancer Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 10-10: Global Janus Kinase Inhibitors Cancer Clinical Pipeline by Phase (%),

+44 20 8123 2220
info@marketpublishers.com

2017 till 2023
Figure 10-11: Global Janus Kinase Inhibitors Cancer Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 11-1: Ruxolitinib – Average Per Tablet & Packet Cost Analysis (US$)
Figure 11-2: Ruxolitinib – Average & Lifetime Treatment Cost Analysis (US$)
Figure 11-3: Global- Average Price of Ruxolitinib Treatment (US$/Month), 2015-2017
Figure 11-4: Survival Rate of Myelofibrosis Patients Undergoing Ruxolitinib Treatment v/s Best Available Therapy
Figure 11-5: Global - Average Lifetime Expenditure of Myelofibrosis Patient (US$)
Figure 11-6: Global - Average Lifetime Drug & Resource Cost (US$)
Figure 11-7: Global - Average Cost of Complete Treatment of Myelofibrosis Patient (US$)
Figure 11-8: Quality Adjusted Life Years for Ruxolitinib & Best Available Therapy for Myelofibrosis
Figure 11-9: Average Cost of JAK/STAT Inhibitors & Conventional Therapies for Cancer (US$/Month)
Figure 11-10: Complete Treatment Cost of JAK/STAT Inhibitors & Monoclonal Antibody Drug (US$)
Figure 11-11: Treatment Cost of JAK/STAT Inhibitors & CAR-T Cell Therapy for Cancer (US$)
Figure 11-12: Treatment Cost of JAK/STAT Inhibitors & Other Small Molecule Cancer Drugs (US$)
Figure 12-1: Global – Cancer JAK/STAT Inhibitor Market Drivers
Figure 12-2: Global - Challenges for Cancer JAK/STAT Inhibitors Market
Figure 13-1: Global- Cancer JAK/STAT Inhibitors Market Opportunity (US$ Billion), 2018-2023

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 2-1: JAK Mutations in Cancers
Table 2-2: STAT Mutations in Cancers
Table 11-1: Ruxolitinib Price Analysis

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023
Product link: https://marketpublishers.com/r/G18D77FF348EN.html
Price: US$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G18D77FF348EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970